Universal CMV Prophylaxis Mitigates the Risks of Basiliximab Induction in Heart Transplant Recipients at Intermediate Risk (R plus ) for Post-Transplant CMV Complications
Publication
, Conference
Alexy, T; Morris, A; Flattery, M; Ortega-Legaspi, J; Devore, A; Shah, P; Sinha, S; Cole, RT
Published in: JOURNAL OF HEART AND LUNG TRANSPLANTATION
2021
Duke Scholars
Published In
JOURNAL OF HEART AND LUNG TRANSPLANTATION
EISSN
1557-3117
ISSN
1053-2498
Publication Date
2021
Volume
40
Issue
4
Start / End Page
S117 / S117
Related Subject Headings
- Surgery
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Alexy, T., Morris, A., Flattery, M., Ortega-Legaspi, J., Devore, A., Shah, P., … Cole, R. T. (2021). Universal CMV Prophylaxis Mitigates the Risks of Basiliximab Induction in Heart Transplant Recipients at Intermediate Risk (R plus ) for Post-Transplant CMV Complications. In JOURNAL OF HEART AND LUNG TRANSPLANTATION (Vol. 40, pp. S117–S117).
Alexy, T., A. Morris, M. Flattery, J. Ortega-Legaspi, A. Devore, P. Shah, S. Sinha, and R. T. Cole. “Universal CMV Prophylaxis Mitigates the Risks of Basiliximab Induction in Heart Transplant Recipients at Intermediate Risk (R plus ) for Post-Transplant CMV Complications.” In JOURNAL OF HEART AND LUNG TRANSPLANTATION, 40:S117–S117, 2021.
Alexy T, Morris A, Flattery M, Ortega-Legaspi J, Devore A, Shah P, et al. Universal CMV Prophylaxis Mitigates the Risks of Basiliximab Induction in Heart Transplant Recipients at Intermediate Risk (R plus ) for Post-Transplant CMV Complications. In: JOURNAL OF HEART AND LUNG TRANSPLANTATION. 2021. p. S117–S117.
Alexy, T., et al. “Universal CMV Prophylaxis Mitigates the Risks of Basiliximab Induction in Heart Transplant Recipients at Intermediate Risk (R plus ) for Post-Transplant CMV Complications.” JOURNAL OF HEART AND LUNG TRANSPLANTATION, vol. 40, no. 4, 2021, pp. S117–S117.
Alexy T, Morris A, Flattery M, Ortega-Legaspi J, Devore A, Shah P, Sinha S, Cole RT. Universal CMV Prophylaxis Mitigates the Risks of Basiliximab Induction in Heart Transplant Recipients at Intermediate Risk (R plus ) for Post-Transplant CMV Complications. JOURNAL OF HEART AND LUNG TRANSPLANTATION. 2021. p. S117–S117.
Published In
JOURNAL OF HEART AND LUNG TRANSPLANTATION
EISSN
1557-3117
ISSN
1053-2498
Publication Date
2021
Volume
40
Issue
4
Start / End Page
S117 / S117
Related Subject Headings
- Surgery
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology